Open AccessThe influence of tumour fluorodeoxyglucose avidity and cachexia development on patient survival in oesophageal or gastroesophageal junction cancer
Author(s) -
Olaechea Santiago,
Gannavarapu Bhavani S.,
Gilmore Anne,
Alvarez Christian,
Iyengar Puneeth,
Infante Rodney
Publication year - 2021
Publication title -
jcsm clinical reports
Language(s) - English
Resource type - Journals
ISSN - 2521-3555
DOI - 10.1002/crt2.42
Subject(s) - cachexia , medicine , weight loss , cancer , esophageal cancer , gastroenterology , primary tumor , clinical endpoint , oncology , metastasis , obesity , randomized controlled trial
Background Cancer cachexia is manifested by loss in muscle, adipose, weight, and appetite. PET 18 F‐FDG uptake identifies tumour metabolic and inflammatory changes, potentially associated with cachexia development. We examined if primary gastroesophageal tumour 18 F‐FDG uptake correlates with cachexia development and survival in cancer patients. Methods One hundred twenty‐six oesophageal ( n = 87) and gastroesophageal junction ( n = 39) cancer patients, with a median age at diagnosis of 63 years (IQR 54–71), evaluated between 2006 and 2014 with pre‐treatment PET imaging and cachexia determination at diagnosis were included in the study cohort (22.1% female; 6.7%, 24.4%, 50.4%, and 18.5% with tumour stage I, II, III, and IV, respectively). Maximum primary tumour standardized uptake values were obtained and dichotomized based off the calculated cut‐point SUV Max of 8.5 ( P = 0.0018). Associations between survival, cachexia development, and primary tumour 18 F‐FDG uptake were evaluated using univariate and multivariate analyses. Results Cancer‐associated weight loss (cachexia) and primary tumour SUV Max at or above the statistically determined cut‐point of 8.5 were present in 54% and 57% of patients, respectively. Primary tumour SUV Max above the cut‐point was significantly associated with pre‐treatment cancer‐associated weight loss ( P = 0.0033) and, in multivariate analysis, correlated with a 2.3‐fold increased risk of death (95% CI 1.4, 3.7; P = 0.0010). When divided into cohorts defined by their combined cachexia and high versus low SUV Max tumour status, positive cachexia status or/and high SUV Max tumours were associated with similar significant decrements in survival. Conclusion A positive association was present between cancer‐associated weight loss and SUV Max of the primary tumour, suggesting greater glycolytic metabolism in gastroesophageal tumours that induce cachexia. This interpretation of routinely administered PET scans could lead to earlier categorization of patients with cachexia‐inducing tumours. Both cachexia and high SUV Max status were independently associated with worsened survival outcomes, further supporting their prognostic relevance in patients with gastroesophageal cancer.